Eli Lilly and Co.

Lab used by Lilly, peers accused of animal cruelty

September 8, 2010
 IBJ Staff and Associated Press
An investigation found that lab employees kicked, threw, and dragged dogs; lifted rabbits by their ears and puppies by their throats; violently slammed cats into cages; and exposed animals to toxic chemicals.
More

CEO says Lilly still not interested in huge acquisitions

September 7, 2010
 IBJ Staff and Bloomberg News
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
More

Appeals court ruling upholds Lilly's Evista patents

September 1, 2010
Bloomberg News
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
More

After health reform, Lilly looking for more

September 1, 2010
J.K. Wall
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the bill—and calling for further government efforts to help pharmaceutical research and development.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

A half-century later, Indiana Landmarks returns to roots

August 28, 2010
Cory Schouten
Old Centrum Watch VideoBankrolled by yet another multimillionaire, the historic preservation group is preparing to move into a new headquarters in Old Centrum, a former church now undergoing a big renovation.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Lilly woes take notch out of debt rating

August 25, 2010
J.K. Wall
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s to lower its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based drugmaker will eventually break its string of bad luck on developing new products.
More

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly wins temporary ban on sales of Strattera copies

August 19, 2010
Bloomberg News
The invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug, which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Bad news piles up for Lilly

August 18, 2010
J.K. Wall
What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera, which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on one of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
More

Lilly's Cymbalta helps chronic pain in U.S. review

August 17, 2010
Bloomberg News
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's annual sales.
More

Lilly halts development of Alzheimer's drug

August 17, 2010
 IBJ Staff and Associated Press
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through 2014.
More

Lilly braces for plunge in profits

August 14, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of loss of revenue that it's hard to picture what the company will look like in five years.
More

Life sciences panel pegs bright spots in IndianaRestricted Content

August 14, 2010
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

For Lilly, it's a big one that got away

August 11, 2010
J.K. Wall
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with analysts predicting as much as $2 billion in annual U.S. sales.
More

Court defeat lost in Lilly's gloomy long-term outlook

August 9, 2010
J.K. Wall
Eli Lilly and Co.'s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn from investors, who have shunned the stock because of five looming patent expirations.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

Lilly's second-quarter profits surge 16 percent

July 22, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months ended June 30, even after paying $27 million in severance to laid off employees.
More

Lilly completes $180 million acquisition of Alnara

July 21, 2010
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company developing an enzyme-replacement therapy for disorders of the pancreas.
More

New rules raise stakes for Lilly drug

July 21, 2010
J.K. Wall
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses of the disease.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT